Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial. (2024). SKIN The Journal of Cutaneous Medicine, 8(1), s323. https://doi.org/10.25251/skin.8.supp.323